Low-dose aspirin cuts dementia risk 70% in people with a certain genetic profile
A Monash analysis of ASPREE data finds aspirin linked to far fewer dementia cases in older adults with high platelet-count genetics, but bleeding risk doubled.
Summary
Dementia prevention may depend on your genes. Monash University researchers analyzed genetic data from more than 13,500 older adults in the ASPREE Trial, which earlier found no overall dementia benefit from low-dose aspirin. When they scored participants by genetic tendency toward higher platelet counts, a different picture emerged. Among those in the top 20 percent of scores, 1 percent of aspirin users developed dementia versus 3.3 percent on placebo, roughly a 70 percent lower relative risk. The catch is safety: in that same group, major bleeding occurred in 4.4 percent of aspirin users compared with 2.1 percent on placebo. The findings hint that platelet activity may play a role in dementia and that genetics could someday help decide who benefits from preventive drugs. This is a secondary analysis, so it generates a hypothesis rather than a recommendation. Nobody should start aspirin to prevent dementia based on this work.
Detailed Summary
Dementia is becoming more common as populations age, and no inexpensive, widely applicable prevention strategy exists. Aspirin has been a candidate for years, but the large ASPREE Trial found no protective effect when all participants were analyzed together. A new Monash University analysis asks whether that average result hid real benefit in a subgroup.
Researchers examined genetic data from more than 13,500 ASPREE participants, all older adults. They assigned each person a genetic score tied to platelet count, since platelets help form clots and prior research links dementia to platelet activation and aggregation. They then compared dementia rates between aspirin and placebo groups across score levels.
The strongest signal appeared in the top 20 percent of platelet-count genetic scores. There, 1 percent of aspirin users developed dementia compared with 3.3 percent of placebo recipients, a relative risk reduction of about 70 percent. However, major bleeding was also higher in this group: 4.4 percent on aspirin versus 2.1 percent on placebo, roughly double.
The key insight is that a null result across a whole population can mask differences between people. If platelet biology contributes to dementia in some individuals, genetic profiling might eventually help match preventive treatments to those most likely to benefit, replacing one-size-fits-all approaches. The work also strengthens interest in platelets as a possible player in brain aging.
Practically, this does not support taking aspirin for dementia prevention. Low-dose aspirin carries real bleeding risks in older adults, and the bleeding rate here offset the apparent cognitive benefit. Caveats are significant: this is a post hoc genetic subgroup analysis, such findings often fail to replicate, absolute numbers of dementia cases in the subgroup are small, and the participants were mostly older adults in a specific trial population. Independent replication and prospective testing are needed before any clinical use. Anyone considering aspirin should discuss it with a physician.
Key Findings
- ASPREE genetic analysis covered more than 13,500 older adults, testing whether platelet-related genes modify aspirin's effect on dementia.
- In the top 20% of platelet-count genetic scores, dementia occurred in 1% on aspirin versus 3.3% on placebo.
- That gap equals about a 70% lower relative dementia risk, even though the overall ASPREE result was null.
- Major bleeding in the same group was 4.4% with aspirin versus 2.1% with placebo, roughly double.
- Findings suggest genetics might one day guide who receives preventive drugs, but replication is required first.
Methodology
This is a university news release summarizing a secondary genetic analysis of data from the randomized ASPREE Trial, published in Alzheimer's & Dementia. The source is a credible institution and journal, but the article is a press summary and the subgroup finding is exploratory rather than confirmatory.
Study Limitations
Subgroup and genetic-score analyses are prone to false positives and need independent replication. Absolute event counts are small, and the press summary omits confidence intervals, interaction tests and details on the cutoff of the article. Check the original paper for statistical methods, ancestry representation and generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: